Антон Кувайцев
Research Subjects
Антон Кувайцев has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Borys Todurov
Department of Cardiosurgery, X-ray and Extracorporeal Technologies, PL Shupyk National Healthcare University of Ukraine
1 shared publication - Olesia Murakhovska
Bogomolets National Medical University Youth Platform
1 shared publication - І. П. Марчук
Волинська обласна клінічна лікарня, Луцьк, Україна Тернопільський національний медичний університет імені І. Я. Горбачевського МОЗ України, Тернопіль, Україна Волинський національний університет імені Лесі Українки, Луцьк, Україна
1 shared publication Гаврило Ковтун
1 shared publicationМикола Кондратюк
1 shared publicationМихайло Загрійчук
1 shared publication
Latest Publications
- 12 January 2024
- Published by Publishing house Uston Ltd in Actual Problems of Nephrology
- No. 32-33,p. 13-19
РАК НИРКИ З МЕТАСТАТИЧНИМ ТРОМБОЗОМ НИЖНЬОЇ ПОРОЖНИСТОЇ ВЕНИ – СУЧАСНИЙ СТАН ПРОБЛЕМИ ТА ПЕРСПЕКТИВИ РОЗВИТКУ
Introduction. This review is devoted to the analysis of the levels of thrombus propagation in the inferior vena cava and its effect on the prognosis of survival in kidney cancer with metastatic IVC thrombosis. Goal. To analyze in a review article the impact on prognosis of the level of inferior vena cava (IVC) involvement in renal cell carcinoma (RCC) and to investigate the current principles of treatment of RCC with tumor thrombosis of the IVC. Materials and methods. A literature search was conducted and relevant papers were reviewed. Relatively recent papers as well as large series or papers from expert centers are included in the reference list. Results and discussion. Tumor venous thrombosis in RCC is a serious and frequent problem today, and patients with this pathology have a poor prognosis. Although successful removal of tumor thrombus in the renal vein and inferior vena cava can lead to improved long-term survival in more than half of patients, high levels of thrombus are a poor prognostic factor for cancer recurrence. Complete thrombectomy of the inferior vena cava, even in the presence of metastases, provides a better quality of life and can prolong survival. Conclusions. Surgery is the most effective method of treating patients with renal cell carcinoma. Every effort should be made to completely remove the thrombus from the inferior vena cava. New targeted therapy may be promising as adjuvant therapy in this subgroup of patients.
- 12 January 2024
- Published by Publishing house Uston Ltd in Actual Problems of Nephrology
- No. 32-33,p. 13-19
РАК НИРКИ З МЕТАСТАТИЧНИМ ТРОМБОЗОМ НИЖНЬОЇ ПОРОЖНИСТОЇ ВЕНИ – СУЧАСНИЙ СТАН ПРОБЛЕМИ ТА ПЕРСПЕКТИВИ РОЗВИТКУ
Introduction. This review is devoted to the analysis of the levels of thrombus propagation in the inferior vena cava and its effect on the prognosis of survival in kidney cancer with metastatic IVC thrombosis. Goal. To analyze in a review article the impact on prognosis of the level of inferior vena cava (IVC) involvement in renal cell carcinoma (RCC) and to investigate the current principles of treatment of RCC with tumor thrombosis of the IVC. Materials and methods. A literature search was conducted and relevant papers were reviewed. Relatively recent papers as well as large series or papers from expert centers are included in the reference list. Results and discussion. Tumor venous thrombosis in RCC is a serious and frequent problem today, and patients with this pathology have a poor prognosis. Although successful removal of tumor thrombus in the renal vein and inferior vena cava can lead to improved long-term survival in more than half of patients, high levels of thrombus are a poor prognostic factor for cancer recurrence. Complete thrombectomy of the inferior vena cava, even in the presence of metastases, provides a better quality of life and can prolong survival. Conclusions. Surgery is the most effective method of treating patients with renal cell carcinoma. Every effort should be made to completely remove the thrombus from the inferior vena cava. New targeted therapy may be promising as adjuvant therapy in this subgroup of patients.